Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-PSMA-137 in mCRPC
NCT06546527Phase 1Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Radiopharmaceutical, Targeted therapy
01
Overview
Phase 1, open-label, single-arm trial of [177Lu]Lu-PSMA-137 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Peking University First Hospital. Primary endpoint: Incidence of treatment-related adverse events. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
[177Lu]Lu-PSMA-137
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06546527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06546527.